PE20220376A1 - Compuestos triciclicos y su uso - Google Patents
Compuestos triciclicos y su usoInfo
- Publication number
- PE20220376A1 PE20220376A1 PE2021002011A PE2021002011A PE20220376A1 PE 20220376 A1 PE20220376 A1 PE 20220376A1 PE 2021002011 A PE2021002011 A PE 2021002011A PE 2021002011 A PE2021002011 A PE 2021002011A PE 20220376 A1 PE20220376 A1 PE 20220376A1
- Authority
- PE
- Peru
- Prior art keywords
- hydrogen
- halogen
- deuterium
- hydroxy
- optionally substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical group 0.000 abstract 6
- 150000002431 hydrogen Chemical group 0.000 abstract 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 5
- 229910052805 deuterium Inorganic materials 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 239000012824 ERK inhibitor Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- -1 hydroxy, amino Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere al compuesto triciclico de formula (I) o una sal farmaceuticamente aceptable, donde: Z1 y Z2 son independientemente C o N; A es un heteroarilo de 5 miembros que contiene 1 a 4 heteroatomos seleccionados de N, O u S, donde dicho heteroarilo es opcionalmente sustituido con halogeno, hidroxi, entre otros; L esta ausente o es S, O y -NRc, donde Rc es hidrogeno o alquilo C1-C6; Ar es heteroarilo opcionalmente sustituido con halogeno, deuterio, hidroxi, amino, entre otros; R1 es hidrogeno, alquilo C1-C6 opcionalmente sustituido con deuterio, entre otros; R2 es hidrogeno, deuterio, halogeno, hidroxi, entre otros; Ra y Rb son hidrogeno, deuterio, halogeno, entre otros; las lineas punteadas son un enlace simple o doble; R3 a R8 son hidrogeno, deuterio, hidroxi, -CN, entre otros; n es 0 a 2 y m es 0 a 5. Tambien se refiere a una composicion farmaceutica. Adicionalmente, se refiere a un compuesto de formula (III), donde: R9 es un grupo saliente; R10 y R11 son independientemente hidrogeno, halogeno o alquilo C1-C6; R3 a R6 son independientemente hidrogeno, halogeno, entre otros. El compuesto de la presente invencion es un inhibidor de ERK, siendo util en el tratamiento del cancer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910489162 | 2019-06-06 | ||
| CN202010455709 | 2020-05-26 | ||
| PCT/CN2020/094692 WO2020244637A1 (en) | 2019-06-06 | 2020-06-05 | Tricyclic compounds and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220376A1 true PE20220376A1 (es) | 2022-03-16 |
Family
ID=73652463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021002011A PE20220376A1 (es) | 2019-06-06 | 2020-06-05 | Compuestos triciclicos y su uso |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12492210B2 (es) |
| EP (1) | EP3980424A4 (es) |
| JP (1) | JP7628089B2 (es) |
| KR (1) | KR20220024408A (es) |
| CN (3) | CN117486890A (es) |
| AU (1) | AU2020288273B2 (es) |
| BR (1) | BR112021024546A2 (es) |
| CA (1) | CA3140475A1 (es) |
| CL (1) | CL2021003228A1 (es) |
| IL (1) | IL288672B1 (es) |
| MX (1) | MX2021014961A (es) |
| MY (1) | MY209035A (es) |
| PE (1) | PE20220376A1 (es) |
| PH (1) | PH12021553058A1 (es) |
| TW (1) | TWI879771B (es) |
| WO (1) | WO2020244637A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI831855B (zh) | 2018-10-26 | 2024-02-11 | 日商大鵬藥品工業股份有限公司 | 新穎吲唑化合物或其鹽 |
| CA3158793A1 (en) | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| WO2021106230A1 (ja) | 2019-11-29 | 2021-06-03 | 大鵬薬品工業株式会社 | 新規なフェノール化合物又はその塩 |
| IL314554A (en) * | 2022-02-23 | 2024-09-01 | Biohaven Therapeutics Ltd | Pyrazolyl compounds as kv7 channel activators |
| US12466840B2 (en) | 2023-10-20 | 2025-11-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS proteins |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008510810A (ja) * | 2004-08-23 | 2008-04-10 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療または予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としての縮合トリアゾール誘導体 |
| TW200806670A (en) | 2006-04-25 | 2008-02-01 | Merck & Co Inc | Inhibitors of checkpoint kinases |
| WO2009071890A1 (en) * | 2007-12-04 | 2009-06-11 | Ucb Pharma S.A. | Tricyclic kinase inhibitors |
| AU2011316016A1 (en) | 2010-10-13 | 2013-05-30 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2012172093A1 (en) | 2011-06-17 | 2012-12-20 | Merz Pharma Gmbh & Co. Kgaa | Dihydroindolizine derivate as metabotropic glutamate receptor modulators |
| TW201348226A (zh) * | 2012-02-28 | 2013-12-01 | Amgen Inc | 作為ｐｉｍ抑制劑之醯胺 |
| BR112016012844B1 (pt) * | 2013-12-06 | 2023-01-10 | Genentech, Inc | Composto e composições farmacêuticas |
| JP6642942B2 (ja) * | 2013-12-30 | 2020-02-12 | アレイ バイオファーマ、インコーポレイテッド | セリン／トレオニンキナーゼ阻害剤 |
| WO2016162325A1 (en) * | 2015-04-07 | 2016-10-13 | Astrazeneca Ab | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors |
| WO2016192063A1 (en) * | 2015-06-03 | 2016-12-08 | Changzhou Jiekai Pharmatech Co. Ltd | Heterocyclic compounds as erk inhibitors |
| EP3337787B1 (en) * | 2015-08-20 | 2021-03-03 | JS InnoPharm (Shanghai) Ltd. | 1h-pyrazolo[3,4-b]pyridine, 1h-thieno[2,3-c]pyrazole and 1h-indazole carboxamide derivatives and related compounds as extracellular signal-regulated kinases (erk) inhibitors for treating cancer |
| CA3003549A1 (en) * | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer |
| CN110799245B (zh) | 2017-05-16 | 2022-08-09 | 生物医学谷探索股份有限公司 | 用于治疗具有非典型braf突变的癌症的组合物和方法 |
| US11401270B2 (en) | 2017-10-27 | 2022-08-02 | Esteve Pharmaceuticals, S.A. | Alcoxyamino derivatives for treating pain and pain related conditions |
| US20220235005A1 (en) | 2019-06-06 | 2022-07-28 | Basf Se | Fungicidal n-(pyrid-3-yl)carboxamides |
| CA3158793A1 (en) | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
-
2020
- 2020-06-05 IL IL288672A patent/IL288672B1/en unknown
- 2020-06-05 CN CN202311477922.7A patent/CN117486890A/zh active Pending
- 2020-06-05 KR KR1020227000071A patent/KR20220024408A/ko active Pending
- 2020-06-05 MY MYPI2021007224A patent/MY209035A/en unknown
- 2020-06-05 US US17/616,904 patent/US12492210B2/en active Active
- 2020-06-05 PE PE2021002011A patent/PE20220376A1/es unknown
- 2020-06-05 JP JP2021572080A patent/JP7628089B2/ja active Active
- 2020-06-05 EP EP20818650.2A patent/EP3980424A4/en active Pending
- 2020-06-05 AU AU2020288273A patent/AU2020288273B2/en active Active
- 2020-06-05 TW TW109118979A patent/TWI879771B/zh active
- 2020-06-05 MX MX2021014961A patent/MX2021014961A/es unknown
- 2020-06-05 CN CN202311475787.2A patent/CN117486888A/zh active Pending
- 2020-06-05 BR BR112021024546A patent/BR112021024546A2/pt unknown
- 2020-06-05 PH PH1/2021/553058A patent/PH12021553058A1/en unknown
- 2020-06-05 WO PCT/CN2020/094692 patent/WO2020244637A1/en not_active Ceased
- 2020-06-05 CA CA3140475A patent/CA3140475A1/en active Pending
- 2020-06-05 CN CN202080041594.4A patent/CN113966336B/zh active Active
-
2021
- 2021-12-03 CL CL2021003228A patent/CL2021003228A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220315597A1 (en) | 2022-10-06 |
| BR112021024546A2 (pt) | 2022-02-08 |
| JP7628089B2 (ja) | 2025-02-07 |
| MY209035A (en) | 2025-06-17 |
| JP2022535559A (ja) | 2022-08-09 |
| CN113966336A (zh) | 2022-01-21 |
| IL288672B1 (en) | 2025-10-01 |
| CN117486888A (zh) | 2024-02-02 |
| AU2020288273A1 (en) | 2022-01-06 |
| KR20220024408A (ko) | 2022-03-03 |
| CN113966336B (zh) | 2023-11-07 |
| TWI879771B (zh) | 2025-04-11 |
| CL2021003228A1 (es) | 2022-07-22 |
| CN117486890A (zh) | 2024-02-02 |
| MX2021014961A (es) | 2022-01-24 |
| CA3140475A1 (en) | 2020-12-10 |
| IL288672A (en) | 2022-02-01 |
| EP3980424A4 (en) | 2023-03-29 |
| PH12021553058A1 (en) | 2022-07-25 |
| EP3980424A1 (en) | 2022-04-13 |
| US12492210B2 (en) | 2025-12-09 |
| WO2020244637A1 (en) | 2020-12-10 |
| TW202112783A (zh) | 2021-04-01 |
| AU2020288273B2 (en) | 2025-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220376A1 (es) | Compuestos triciclicos y su uso | |
| UY39904A (es) | Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos | |
| PE20241127A1 (es) | Compuestos triciclicos como inhibidores de kras | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20221457A1 (es) | Degradadores de moleculas pequenas de helios y procedimientos de uso | |
| PE20191541A1 (es) | Composiciones y metodos para inhibir la accion de la arginasa | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| PE20091556A1 (es) | Derivado heterociclico fusionado y su uso | |
| PE20220134A1 (es) | Compuestos de pirrolidina | |
| AR011093A1 (es) | Compuestos derivados de sulfonil urea, composicion farmaceutica que los contiene y procedimiento para su uso. | |
| PE20201256A1 (es) | Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas | |
| PE20080093A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
| PE20142098A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| PE20170247A1 (es) | Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1 | |
| MA31419B1 (fr) | Derives de pyridine | |
| PE20090362A1 (es) | Derivados de piperidina/piperazina como moduladores de dgat | |
| PE20170775A1 (es) | Derivados de benzodiazepina citotoxicos | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| AR072809A1 (es) | Compuesto de (3- piridinilcarbonil)-4-(fenilsulfonilpiperazina ), su uso para la elaboracion de unmedicamento para el tratamiento del dolor y composicion farmaceutica que lo comprende | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| PE20070715A1 (es) | Derivados de pirazina | |
| PE20230680A1 (es) | Inhibidores de il4i1 y metodos de uso | |
| PH12022550436A1 (en) | Alpha-d-galactopyranoside derivatives | |
| MX2024013019A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| PE20240652A1 (es) | Compuestos que inhiben la isoforma alfa de pi3k y metodos para tratar el cancer |